/

Empresas

Ca

No verificado

CatalYm

Sobre qué escribimos

FarmacéuticaIndustriaMedicina - VariosOncologíaSalud

9 Comunicados de prensa

Ver todos los comunicados de prensa

07/04/2026

Industria

Ciencia

Biotecnología

Farmacéutica

Oncología

Salud

Medicina - Varios

CatalYm Doses First Patient in Phase 2b Trial Evaluating Visugromab in Combination with Chemoimmunotherapy as Second-Line Treatment in Unresectable/Metastatic Hepatocellular Carcinoma

Fuente

Editor

1.00

0

02/12/2025

Industria

Ciencia

Medicina - Varios

Biotecnología

Sanidad

Salud

Farmacéutica

Oncología

CatalYm Announces First Patient Dosed in Phase 2b Trial Evaluating Visugromab in Combination with Chemoimmunotherapy as Second-Line Treatment in Metastatic Non-squamous NSCLC

Fuente

Editor

1.00

0

17/10/2025

Oncología

Salud

Biotecnología

Sanidad

Medicina - Varios

Farmacéutica

Eventos

Ferias y Congresos

Industria

CatalYm Presents Phase 2 Data in Neoadjuvant Bladder Cancer Demonstrating Substantial Increase of Anti-Tumor Activity for Visugromab in Combination with PD-1 Inhibitor at ESMO

Fuente

Editor

1.00

0

30/09/2025

Ciencia

Biotecnología

Farmacéutica

Oncología

Salud

Medicina - Varios

Industria

CatalYm Announces First Patient Dosed in Phase 2b Trial Evaluating Visugromab in Combination with Chemoimmunotherapy as First-Line Treatment in Metastatic Non-squamous NSCLC

Fuente

Editor

1.00

0

22/09/2025

Ferias y Congresos

Industria

Oncología

Salud

Medicina - Varios

Ciencia

Farmacéutica

CatalYm to Present Primary Results From Phase 2 Neoadjuvant Bladder Cancer Trial in Late-breaking Oral Presentation at ESMO

Fuente

Editor

1.00

0

09/01/2025

Mercado laboral

Ciencia

Biotecnología

Farmacéutica

Oncología

Salud

Medicina - Varios

CatalYm Appoints Scott Clarke CEO as Company Initiates Global Phase 2b Clinical Development Program for Visugromab

Fuente

Editor

1.00

0

11/12/2024

Ciencia

Medicina - Varios

Biotecnología

Sanidad

Salud

Farmacéutica

Oncología

Industria

CatalYm’s Visugromab Phase 1/2a Data Demonstrating Clinical Proof-of-Concept for Reversing Resistance to Checkpoint Inhibitors through GDF-15 Neutralization Published in Nature

Fuente

Editor

1.00

0

10/12/2024

Eventos

Industria

Oncología

Salud

Medicina - Varios

Ciencia

Farmacéutica

Biotecnología

CatalYm Highlights Visugromab’s Potential to Treat Cachexia in Cancer Patients at International SCWD Conference

Fuente

Editor

1.00

0

16/07/2024

Ciencia

Finanzas

Medicina - Varios

Asociaciones/Profesionales

Biotecnología

Sanidad

Farmacéutica

Salud

Oncología

Industria

CatalYm Announces New Financing of $150M to Support Broad Phase 2b Development Program for Visugromab

Fuente

Editor

1.00

0

Seguidores

0

Compatibilidad

0